Amarin borrows $100m to launch Vascepa but keeps alliance door open
This article was originally published in Scrip
Executive Summary
Amarin's stock price fell 18.4% to $9.75 per share in after-hours trading on 6 December after the company announced that it raised $100 million in non-equity financing from an investment fund managed by Pharmakon Advisors to support commercialization of its prescription fish oil pill Vascepa (icosapent ethyl) without a partner.